详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. [2]Department of Hematology, Shengli Oilfield Central Hospital, Dongying, 257034, Shandong, People's Republic of China. [3]Department of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China. [4]Clinical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, Guangdong, People's Republic of China. [5]Department of Pediatrics, Shengli Oilfield Central Hospital, Dongying, 257034, Shandong, People's Republic of China. [6]Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China.

出处：

DOI：

ISSN：

关键词： Histone deacetylase HDACi PTCL Romidepsin Belinostat Chidamide

摘要：

Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy. Currently, several novel targeted agents, including histone deacetylase inhibitors (HDACis), have been investigated to improve the therapeutic outcome of PTCLs. Several HDACis, such as romidepsin, belinostat, and chidamide, have demonstrated favorable clinical efficacy and safety in PTCLs. More novel HDACis and new combination therapies are undergoing preclinical or clinical trials. Mutation analysis based on next-generation sequencing may advance our understanding of the correlation between epigenetic mutation profiles and relevant targeted therapies. Multitargeted HDACis and HDACi-based prodrugs hold promising futures and offer further directions for drug design.© 2023. The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区遗传学 2 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区遗传学 2 区肿瘤学

第一作者：

第一作者机构： [1]Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. [2]Department of Hematology, Shengli Oilfield Central Hospital, Dongying, 257034, Shandong, People's Republic of China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat [2]Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. [3]Regulation of histone acetyltransferase TIP60 function by histone deacetylase 3. [4]Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells. [5]A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China [6]Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. [7]A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas. [8]Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells. [9]Novel histone deacetylase inhibitor N25 exerts anti-tumor effects and induces autophagy in human glioma cells by inhibiting HDAC3 [10]Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization